Cited by 324Inflammatory Bowel DiseaseCytokine Signaling Pathways and InteractionsPsoriasis: Treatment and Pathogenesis

The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.

Involvement of IL–6 in the pathogenesis of inflammatory bowel disease and colon cancer

Atreya, Raja, Neurath, Markus F.·2005·Clinical Reviews in Allergy & Immunology

Open this paper in CoChat — free account

Abstract

Inflammatory bowel disease (IBD), which consists of Crohn's disease and ulcerative colitis, is defined as a chronic inflammation of the gastrointestinal tract. The etiopathogenetic mechanisms underlying the development of IBD are still not completely understood, and the therapeutic strategies used thus far have been limited to mostly evidence-based principles. There is growing evidence that the pro-inflammatory cytokine interleukin (IL)-6 plays a crucial part in the uncontrolled intestinal inflammatory process, which is a main characteristic of IBD. There is elevated production of IL-6 and its soluble receptor (sIL-6R) by intestinal macrophages and CD4+T-cells. The increased formation of IL-6-sIL-6R complexes that interact with gp130 on the membrane of CD4+T-cells (trans-signaling) lead to an increased expression and nuclear translocation of STAT3, which causes the induction of anti-apoptotic genes, such as Bcl-xl. This leads to an augmented resistance of lamina propria T-cells to apoptosis. The ensuing T-cell expansion contributes to the perpetuation of chronic intestinal inflammation. This understanding concerning the predominant pathogenic role of an IL-6-dependent inflammatory cascade may lead to the development of new therapeutic strategies in the treatment of this disease. Recent studies have also suggested a potential role of IL-6-sIL-6R in the pathogenesis of colon cancer and, therefore, imply a possible novel therapeutic strategy targeting the sIL-6R and ensuing IL-6 trans-signaling.

Integrity signals

Registry

Crossref · 10.1385/criai:28:3:187

Cites

57 of 57 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Inflammatory Bowel Disease
Podolsky, D. K. (2002) · New England Journal of Medicine · doi:10.1056/nejmra020831 · Cited by 3,183
The risk of colorectal cancer in ulcerative colitis: a meta-analysis
Eaden, J., Abrams, K. R., & Mayberry, J. F. (2001) · Gut · doi:10.1136/gut.48.4.526 · Cited by 2,948
Inflammatory bowel disease: Etiology and pathogenesis
Fiocchi, C. (1998) · Gastroenterology · doi:10.1016/s0016-5085(98)70381-6 · Cited by 2,059
Ulcerative Colitis and Colorectal Cancer
Ekbom, A., Helmick, C. G., Zack, M. M., & Adami, H. (1990) · New England Journal of Medicine · doi:10.1056/nejm199011013231802 · Cited by 1,794
Impaired immune and acute-phase responses in interleukin-6-deficient mice
Kopf, M., Baumann, H., Freer, G., Freudenberg, M., Lamers, M., Kishimoto, T., Zinkernagel, R., Bluethmann, H., & Köhler, G. (1994) · Nature · doi:10.1038/368339a0 · Cited by 1,768
Interleukin-6 triggers the association of its receptor with a possible signal transducer, gp130
Taga, T., Hibi, M., Hirata, Y., Yamasaki, K., Yasukawa, K., Matsuda, T., Hirano, T., & Kishimoto, T. (1989) · Cell · doi:10.1016/0092-8674(89)90438-8 · Cited by 1,396
Antibodies to interleukin 12 abrogate established experimental colitis in mice.
Neurath, M., Fuss, I. J., Kelsall, B. L., Stuber, E. R., & Strober, W. (1995) · The Journal of Experimental Medicine · doi:10.1084/jem.182.5.1281 · Cited by 1,334
Self-citation
Blockade of interleukin 6 trans signaling suppresses T-cell resistance against apoptosis in chronic intestinal inflammation: evidence in Crohn disease and experimental colitis in vivo
Atreya, R., Mudter, J., Finotto, S., Müllberg, J., Jostock, T., Wirtz, S., Schütz, M., Bartsch, B., Holtmann, M., Becker, C., et al. (2000) · Nature Medicine · doi:10.1038/75068 · Cited by 1,293
Self-citation
Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-γ, whereas ulcerative colitis LP cells manifest increased secretion of IL-5
Fuss, I. J., Neurath, M. F., Boirivant, M., Klein, J. S., de la Motte, C., Strong, S. A., Fiocchi, C., & Strober, W. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.3.1261 · Cited by 1,227
Self-citation
Inflammatory Bowel Disease
Podolsky, D. K. (1991) · New England Journal of Medicine · doi:10.1056/nejm199109263251306 · Cited by 1,226
Annual Report to the Nation on the Status of Cancer, 1975-2000, Featuring the Uses of Surveillance Data for Cancer Prevention and Control
Weir, H. K. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djg040 · Cited by 864
Enhand secretion of tumour necrosis factor-alpha, IL-6, and IL-1β by isolated lamina ropria monouclear cells from patients with ulcretive cilitis and Crohn's disease
REINECKER, H.-C., STEFFEN, M., Witthoeft, T., Pflüger, I., Schreiber, S., MacDermott, R. P., & Raedler, A. (1993) · Clinical & Experimental Immunology · doi:10.1111/j.1365-2249.1993.tb05997.x · Cited by 855
Soluble receptors for cytokines and growth factors: generation and biological function
Rose‐John, S., & Heinrich, P. C. (1994) · Biochemical Journal · doi:10.1042/bj3000281 · Cited by 777
TGF-β Suppresses Tumor Progression in Colon Cancer by Inhibition of IL-6 trans-Signaling
Becker, C., Fantini, M. C., Schramm, C., Lehr, H. A., Wirtz, S., Nikolaev, A., Burg, J., Strand, S., Kiesslich, R., Huber, S., et al. (2004) · Immunity · doi:10.1016/j.immuni.2004.07.020 · Cited by 726
Self-citation
Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn’s disease
van den Brande, J. M. H., Braat, H., BRINK, G. R. V. D., Versteeg, H. H., Bauer, C. A., Hoedemaeker, I., van Montfrans, C., Hommes, D. W., Peppelenbosch, M. P., & van Deventer, S. J. H. (2003) · Gastroenterology · doi:10.1016/s0016-5085(03)00382-2 · Cited by 722
A pilot randomized trial of a human anti-interleukin-6 receptor monoclonal antibody in active Crohn’s disease☆
Ito, H., Takazoe, M., Fukuda, Y., Hibi, T., Kusugami, K., Andoh, A., Matsumoto, T., Yamamura, T., Azuma, J., & Nishimoto, N. (2004) · Gastroenterology · doi:10.1053/j.gastro.2004.01.012 · Cited by 636
The role of Th1/Th2 polarization in mucosal immunity
Neurath, M. F., Finotto, S., & Glimcher, L. H. (2002) · Nature Medicine · doi:10.1038/nm0602-567 · Cited by 628
Self-citation
Intestinal permeability and the prediction of relapse in Crohn's disease
Wyatt, J., Vogelsang, H., Hübl, W., Waldhoer, T., & Lochs, H. (1993) · The Lancet · doi:10.1016/0140-6736(93)90882-h · Cited by 626
Cytokines in intestinal inflammation: Pathophysiological and clinical considerations
Sartor, R. B. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90614-9 · Cited by 595
Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells
Monteleone, G., Biancone, L., Marasco, R., Morrone, G., Marasco, O., Luzza, F., & Pallone, F. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70128-8 · Cited by 571
Crohn's disease
Shanahan, F. (2002) · The Lancet · doi:10.1016/s0140-6736(02)07284-7 · Cited by 478
IL-6 is required for the development of Th1 cell-mediated murine colitis
Yamamoto, M., Yoshizaki, K., Kishimoto, T., & Ito, H. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.9.4878 · Cited by 411
Intestinal cancer risk and mortality in patients with Crohn's disease
Munkholm, P., Langholz, E., Davidsen, M., & Binder, V. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)91068-s · Cited by 379
Complex of soluble human IL-6-receptor/IL-6 up-regulates expression of acute-phase proteins
Mackiewicz, A. A., Schooltink, H., Heinrich, P. C., & Rose‐John, S. (1992) · The Journal of Immunology · doi:10.4049/jimmunol.149.6.2021 · Cited by 369
Serum interleukin‐6 levels reflect the disease status of colorectal cancer
Chung, Y., & Chang, Y. (2003) · Journal of Surgical Oncology · doi:10.1002/jso.10269 · Cited by 354
Resistance of Crohn’s Disease T Cells to Multiple Apoptotic Signals Is Associated with a Bcl-2/Bax Mucosal Imbalance
Ina, K., Itoh, J., Fukushima, K., Kusugami, K., Yamaguchi, T., Kyokane, K., Imada, A., Binion, D. G., Musso, A., West, G. A., et al. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.2.1081 · Cited by 347
Cytokine messenger RNA profiles in inflammatory bowel disease mucosa detected by polymerase chain reaction amplification
Isaacs, K. L., Sartor, R. B., & Haskill, S. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)91182-4 · Cited by 305
Development of chronic colitis is dependent on the cytokine MIF
de Jong, Y. P., Abadía‐Molina, A. C., Satoskar, A. R., Clarke, K., Rietdijk, S. T., Faubion, W. A., Mizoguchi, E., Metz, C. N., Sahli, M. A., ten Hove, T., et al. (2001) · Nature Immunology · doi:10.1038/ni720 · Cited by 305
Evidence for continuous stimulation of interleukin-6 production in Crohn's disease
Groß, V., Andus, T., Caesar, I., Roth, M., & Schölmerich, J. (1992) · Gastroenterology · doi:10.1016/0016-5085(92)90098-j · Cited by 293
Lamina propria T cells in Crohn's disease and other gastrointestinal inflammation show defective CD2 pathway-induced apoptosis
Boirivant, M., Marini, M., Felice, G. D., Pronio, A., Montesani, C., Tersigni, R., & Strober, W. (1999) · Gastroenterology · doi:10.1016/s0016-5085(99)70177-0 · Cited by 267
Prognostic Significance of Circulating IL-10 and IL-6 Serum Levels in Colon Cancer Patients Undergoing Surgery
Galizia, G., Orditura, M., Romano, C. P., Lieto, E., Castellano, P., Pelosio, L., Imperatore, V., Catalano, G., Pignatelli, C., & Vita, F. D. (2002) · Clinical Immunology · doi:10.1006/clim.2001.5163 · Cited by 228
Distinct cytokine patterns in early and chronic ileal lesions of Crohn's disease
Desreumaux, P., Brandt, E. B., Gambiez, L. P., Émilie, D., Geboes, K., Klein, O., Ectors, N., Cortot, A., Capron, M., & Colombel, J.-F. (1997) · Gastroenterology · doi:10.1016/s0016-5085(97)70116-1 · Cited by 219
C-reactive Protein: A Physiological Activator of Interleukin 6 Receptor Shedding
Jones, S. A., Novick, D., Horiuchi, S., Yamamoto, N., Szalai, A. J., & Fuller, G. M. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.189.3.599 · Cited by 200
Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6.
Mitsuyama, K., Toyonaga, A., Sasaki, E., Ishida, O., Ikeda, H., Tsuruta, O., Harada, K., Tateishi, H., Nishiyama, T., & Tanikawa, K. (1995) · Gut · doi:10.1136/gut.36.1.45 · Cited by 185
High circulating concentrations of interleukin-6 in active Crohn's disease but not ulcerative colitis.
Mahida, Y. R., Kurlac, L., Gallagher, A., & Hawkey, C. J. (1991) · Gut · doi:10.1136/gut.32.12.1531 · Cited by 184
Tissue cytokine and chemokine expression in inflammatory bowel disease
McCormack, G. W., Moriarty, D. C., O’Donoghue, D., McCormick, P. A., Sheahan, K. D., & Baird, A. W. (2001) · Inflammation Research · doi:10.1007/pl00000223 · Cited by 181
Mucosal proinflammatory cytokine production correlates with endoscopic activity of ulcerative colitis
Ishiguro, Y. (1999) · Journal of Gastroenterology · doi:10.1007/s005350050218 · Cited by 175
Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells.
Schneider, M. R., Hoeflich, A., Fischer, J. R., Wolf, E., Sordat, B., & Lahm, H. (2000) · Cancer Letters · doi:10.1016/s0304-3835(99)00401-2 · Cited by 167
Elevation of interleukin-6 in inflammatory bowel disease is macrophage- and epithelial cell-dependent
Kusugami, K., Fukatsu, A., Tanimoto, M., Shinoda, M., Haruta, J.-I., Kuroiwa, A., Ina, K., Kanayama, K., Ando, T., Matsuura, T., et al. (1995) · Digestive Diseases and Sciences · doi:10.1007/bf02064182 · Cited by 151
Clinical relevance of serum interleukin-6 in Crohn’s disease: single point measurements, therapy monitoring, and prediction of clinical relapse
Reinisch, W., Gasché, C., Tillinger, W., Wyatt, J., Lichtenberger, C., Willheim, M., Dejaco, C., Waldhör, T., Bakos, S., Vogelsang, H., et al. (1999) · American Journal of Gastroenterology · doi:10.1111/j.1572-0241.1999.01288.x · Cited by 150
Relationship of functional and antigenic interleukin 6 to disease activity in inflammatory bowel disease
Hyams, J. S., Fitzgerald, J. E., Treem, W. R., Wyzga, N., & Kreutzer, D. L. (1993) · Gastroenterology · doi:10.1016/0016-5085(93)90336-b · Cited by 146
Detection of mRNAs for macrophage products in inflammatory bowel disease by in situ hybridisation.
Cappello, M., Keshav, S., Prince, C., Jewell, D. P., & Gordon, S. (1992) · Gut · doi:10.1136/gut.33.9.1214 · Cited by 134
Decreased Bax expression by mucosal T cells favours resistance to apoptosis in Crohn's disease
Itoh, J. (2001) · Gut · doi:10.1136/gut.49.1.35 · Cited by 130
Interleukin-6 and soluble interleukin-6 receptor in the colonic mucosa of inflammatory bowel disease
Hosokawa, T., Kusugami, K., Ina, K., Ando, T., Shinoda, M., Imada, A., Ohsuga, M., Sakai, T., Matsuura, T., Ito, K., et al. (1999) · Journal of Gastroenterology and Hepatology · doi:10.1046/j.1440-1746.1999.01989.x · Cited by 112
Human intestinal epithelial cells secrete interleukin-1 receptor antagonist and interleukin-8 but not interleukin-1 or interleukin-6
Daig, R., Rogler, G., Aschenbrenner, E., Vogl, D., Falk, W., Gross, V., Schölmerich, J., & Andus, T. (2000) · Gut · doi:10.1136/gut.46.3.350 · Cited by 104
Pore-forming toxins trigger shedding of receptors for interleukin 6 and lipopolysaccharide.
Walev, I., Vollmer, P., Palmer, M., Bhakdi, S., & Rose‐John, S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.15.7882 · Cited by 102
A high serum concentration of interleukin-6 is predictive of relapse in quiescent Crohn??s disease
Louis, E. J., Bélaïche, J., Kemseke, C. V., Franchimont, D. P., Groote, D. D., Gueenen, V., & Mary, J. (1997) · European Journal of Gastroenterology & Hepatology · doi:10.1097/00042737-199710000-00004 · Cited by 101
Novel pathogenic mechanism of microbial metalloproteinases: liberation of membrane-anchored molecules in biologically active form exemplified by studies with the human interleukin-6 receptor
Vollmer, P., Walev, I., Rose‐John, S., & Bhakdi, S. (1996) · Infection and Immunity · doi:10.1128/iai.64.9.3646-3651.1996 · Cited by 98
Interrelations between interleukin-6, interleukin-1 beta, plasma C-reactive protein values, and in vitro C-reactive protein generation in patients with inflammatory bowel disease.
Mazlam, M. Z., & Hodgson, H. J. F. (1994) · Gut · doi:10.1136/gut.35.1.77 · Cited by 90
Frequently relapsing Crohn's disease is characterized by persistent elevation in interleukin-6 and soluble interleukin-2 receptor serum levels during remission
Kemseke, C. V., Bélaïche, J., & Louis, E. J. (2000) · International Journal of Colorectal Disease · doi:10.1007/s003840000226 · Cited by 72
Lamina propria and circulating interleukin-6 in newly diagnosed pediatric inflammatory bowel disease patients
Brown, K. A., Back, S. J., Ruchelli, E. D., Markowitz, J. E., Mascarenhas, M. R., Verma, R., Piccoli, D. A., & Baldassano, R. N. (2002) · The American Journal of Gastroenterology · doi:10.1111/j.1572-0241.2002.06030.x · Cited by 54
Bax is downregulated in inflamed colonic mucosa of ulcerative colitis
Iimura, M., Nakamura, T., Shinozaki, S., Iizuka, B., Inoue, Y., Suzuki, S., & Hayashi, N. (2000) · Gut · doi:10.1136/gut.47.2.228 · Cited by 53
Cytokine messenger RNA expression and proliferation status of intestinal mononuclear cells in noninflamed gut and Crohn's disease
Autschbach, F., Qiao, L., Wallich, R., Meuer, S. C., Sch�rmann, G., & Merz, H. (1995) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf00194698 · Cited by 53
The expanding role of biological agents in the treatment of inflammatory bowel disease – focus on selective adhesion molecule inhibition
Rutgeerts, P., van Deventer, S., & Schreiber, S. (2003) · Alimentary Pharmacology & Therapeutics · doi:10.1046/j.1365-2036.2003.01603.x · Cited by 41
Increased interleukin-6 levels, interleukin-6 receptor and gp130 expression in peripheral lymphocytes of patients with inflammatory bowel disease.
Holub, M., Makó, E., Dévay, T., Dank, M., Szalai, C., Fenyvesi, A., & Falus, A. (1998) · PubMed · Cited by 35
Protective and pathogenic roles of cytokines in inflammatory bowel diseases.
Mf, N., & Büschenfelde, K. H. M. Z. (1996) · PubMed · Cited by 19
Mucosal Interleukin-6 Secretion in Ulcerative Colitis: Effects of Anti-Inflammatory Drugs and T-Cell Stimulation
Jones, S., Crabtree, J. E., Rembacken, B. J., Dixon, M. F., Trejdosiewicz, L. K., Hicher, J. T., & Axon, A. T. R. (1994) · Scandinavian Journal of Gastroenterology · doi:10.3109/00365529409092500 · Cited by 14

Flagged first, then by citations

Sorted by citations

Inflammation and Colon Cancer
Terzić, J., Grivennikov, S., Karin, E., & Karin, M. (2010) · Gastroenterology · doi:10.1053/j.gastro.2010.01.058 · Cited by 1,974
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer
Grivennikov, S., Karin, E., Terzic, J., Mucida, D., Yu, G.-Y., Vallabhapurapu, S., Scheller, J., Rose-John, S., Cheroutre, H., Eckmann, L., et al. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.001 · Cited by 2,155
Targeting interleukin-6 in inflammatory autoimmune diseases and cancers
Yao, X., Huang, J., Zhong, H., Shen, N., Faggioni, R., Fung, M. S. C., & Yao, Y. (2013) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2013.09.004 · Cited by 677
Induction of Osteogenesis in Mesenchymal Stem Cells by Activated Monocytes/Macrophages Depends on Oncostatin M Signaling
Guihard, P. J., Danger, Y., Royer, B. B.-L., David, E., Brion, R., Delécrin, J., Richards, C. D., Chevalier, S., Rédiní, F., Heymann, D., et al. (2012) · Stem Cells · doi:10.1002/stem.1040 · Cited by 477
Inflammatory cytokines in cancer: tumour necrosis factor and interleukin 6 take the stage
Grivennikov, S. I., & Karin, M. (2011) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2010.140145 · Cited by 560

See all 324

Authors: Atreya, R., & Neurath, M. F.
Affiliations: Johannes Gutenberg University Mainz (DE)
Corresponding author: Neurath, Markus F.
ORCID: Atreya, Raja
Neurath, Markus F.
Venue: Clinical Reviews in Allergy & Immunology
Publisher: Springer Science and Business Media LLC
Published: 2005
Volume: 28
Issue: 3
Pages: 187-196
ISSN: 1080-0549 (ISSN-L)
DOI: 10.1385/criai:28:3:187
OpenAlex: W2024255214
Cited by: 324
References: 57
Citations by year: 2026: 11 · 2025: 16 · 2024: 21 · 2023: 23 · 2022: 22 · 2021: 25 · 2020: 22 · 2019: 9 · 2018: 17 · 2017: 13 · 2016: 20 · 2015: 13 · 2014: 13 · 2013: 13 · 2012: 12
FWCI: 4.82
Type: journal article
Language: en
Open access: closed
Locations: Clinical Reviews in Allergy & Immunology (publishedVersion)
PubMed (publishedVersion)
Topics: Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
Life Sciences › Immunology and Microbiology › Immunology › Cytokine Signaling Pathways and Interactions
Life Sciences › Immunology and Microbiology › Immunology › Psoriasis: Treatment and Pathogenesis
Keywords: interleukin-6, inflammatory bowel disease, Crohn's disease, ulcerative colitis, colon cancer, soluble IL-6 receptor, IL-6 trans-signaling, gp130, STAT3, Bcl-xL, T cell apoptosis, intestinal inflammation, CD4+ T cells, macrophages, anti-apoptotic genes
MeSH terms: Animals, Humans, Colorectal Neoplasms, Inflammatory Bowel Diseases, Interleukin-6

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Involvement of IL–6 in the pathogenesis of inflammatory bowel disease and colon cancer

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks